ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

MXC Mgc Pharmaceuticals Limited

22.00
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Mgc Pharmaceuticals Limited LSE:MXC London Ordinary Share AU000000MXC6 ORD NPV (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 22.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Drug & Proprietary Stores 3.02M -17.53M -0.3998 -0.38 9.65M
Mgc Pharmaceuticals Limited is listed in the Drug & Proprietary Stores sector of the London Stock Exchange with ticker MXC. The last closing price for Mgc Pharmaceuticals was 22p. Over the last year, Mgc Pharmaceuticals shares have traded in a share price range of 17.50p to 27.00p.

Mgc Pharmaceuticals currently has 43,851,631 shares in issue. The market capitalisation of Mgc Pharmaceuticals is £9.65 million. Mgc Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.38.

Mgc Pharmaceuticals Share Discussion Threads

Showing 17551 to 17573 of 17575 messages
Chat Pages: 703  702  701  700  699  698  697  696  695  694  693  692  Older
DateSubjectAuthorDiscuss
10/4/2024
20:55
Driven your company into the ground? Failed to deliver a single one of the promises made to shareholders? Out of money and investor sentiment? Need a new flock of gullible sheep to fleece? Simples - just change your name and start over. Rinse and repeat...
sloppyjoe2
05/4/2024
16:35
Well I'm sure the name change will solve all the companies problems and create value for all shareholders FFS
cal57
03/4/2024
10:22
No doubt the change of name to comply with LSE rules
looneytune
03/4/2024
10:12
What is these suspension about ?
kenbos
21/3/2024
10:24
Argent Biopharma Ltd it is then...
heatseek77
21/3/2024
10:22
Tbh graft polymer separate entity
heatseek77
15/3/2024
13:12
FRAUDSTER WOW GET IUT WHILE YIU CAN MUST BE WORTH ABOUT 00000001p old money lol . LSE should be sued Roby Zomer, outgoing Chairman, commented: "The shocking conflicts taking place in the Middle East, Ukraine and the Red Sea have had a major impact on the Company and conspired to undermine our business development plans. With the severe constraints on our ability to trade, our financial position has become parlous, forcing the Company to undertake an urgent review of its future direction. "We thank Nicholas and the other lender for providing us with interim working capital. Nicholas's priority as the incoming Chairman is to establish sources of additional funding whilst working with the board to consider the best future for Graft Polymer."
aimscam1
15/3/2024
13:10
I WOULD GET OUT WHILE YOU CAN THIS IS GOJNG SAME WAY . Total Fraudster and scum . Had 100 million from this company since 2016 which started in Australia GFG called this correct . Roby Zomer, outgoing Chairman, commented: "The shocking conflicts taking place in the Middle East, Ukraine and the Red Sea have had a major impact on the Company and conspired to undermine our business development plans. With the severe constraints on our ability to trade, our financial position has become parlous, forcing the Company to undertake an urgent review of its future direction. "We thank Nicholas and the other lender for providing us with interim working capital. Nicholas's priority as the incoming Chairman is to establish sources of additional funding whilst working with the board to consider the best future for Graft Polymer."
aimscam1
14/2/2024
08:25
Profit moving to APH
blackhorse23
13/2/2024
10:18
The CEO may or may not be corrupt, but I fail to see what his religion has to do with anything.
sloppyjoe2
09/2/2024
19:07
Have to agree with you
kenbos
01/2/2024
14:13
Even the mms are struggling to move this can't believe I bought some of these but I did glad it was only a small punt
kenbos
31/1/2024
07:52
Why has there latest update got a chart from 2021 in it ???
blue377
31/1/2024
07:49
Most corrupt company on aim
ic0gcds00
16/1/2024
08:48
Absolutely nothing coming out news wise what happened it was meant to be ready for production and sales were meant to be growing but nothing at all happening my worst investment by a long way oh well ya pays your money and takes ur chances big mistake on this one
kenbos
19/12/2023
08:12
Real news:-

MGC Pharmaceuticals Limited ArtemiC(TM) receives FDA Approval in Saudi Arabia
19/12/2023 7:57am
RNS Non-Regulatory

TIDMMXC
MGC Pharmaceuticals Limited
19 December 2023
MGC Pharmaceuticals Ltd.
ArtemiC(TM) receives FDA Approval in Saudi Arabia
19 December 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd (MGC Pharma, MGC or the Company), a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, is pleased to announce that it has been granted approval for its proprietary product ArtemiC(TM) by the Food and Drug Authority in the Kingdom of Saudi Arabia (Saudi FDA).
Following the success of Phase II clinical trials[1] and European studies on its effectiveness in assisting with the recovery of patients from Covid and long-term Covid, ArtemiC(TM) has now been approved by the Saudi FDA as an over-the-counter (OTC) dietary supplement.
In addition, MGC Pharma appointed specialist consultancy Capital Blossom Ltd in 2022 as its agent to the Kingdom of Saudi Arabia, Sultanate of Oman, United Arab Emirates, Bahrain, Kuwait, and Qatar.
Capital Blossom, through its joint venture collaboration with its Saudi partner have worked on obtaining the approval of the Saudi FDA.
Roby Zomer, CEO and Managing Director of MGC, commented : "We are delighted to receive Saudi FDA approval for ArtemiC(TM) which validates our product and follows the progress we had in USA earlier this year. We are hopeful this will materialise into commercial orders for MGC as we work closely with Capital Blossom Ltd who are specialists in this territory.
About ArtemiC(TM)
ArtemiC(TM) is a clinically tested product. Developed by MGC Pharma, it incorporates GraftBio(R) SNEDD technology, which increases the bioavailability of ArtemiC(TM)'s active ingredients.
In a Phase II double-blind, placebo-controlled Clinical Trial on 50 patients with COVID-19, ArtemiC(TM) demonstrated the following advantages:
-- A full safety and efficacy profile with no drug-adverse events.
-- The ability to prevent deterioration of COVID-19 patients and achieve faster clinical improvement.
-- The ability to reduce symptoms and pain associated with COVID-19.
- Ends-

looneytune
18/12/2023
11:42
Another meaningless rns
kenbos
12/12/2023
19:18
This company should be thrown off and everybody in it put in jail
ic0gcds00
08/12/2023
16:15
Very quiet on here how much has been produced in Malta ?
kenbos
16/11/2023
09:26
40s coming -
tomboyb
15/11/2023
15:54
Indeed -

Patience is a virtue -

tomboyb
15/11/2023
15:52
Bought in last week having followed this for what seems an eternity. Money troubles out of the way for a little while now allowing them to concentrate on selling the story and growing the take up. Its been a horrendous time foe those who had stuck with it but for those still remaining this is surely a turning point.
marvelman
15/11/2023
09:48
Virtually no stock -
tomboyb
Chat Pages: 703  702  701  700  699  698  697  696  695  694  693  692  Older

Your Recent History

Delayed Upgrade Clock